摘要
Objective:To analyze the efficacy of capecitabine(referred to as Cap)single-agent maintenance therapy in the advanced breast cancer.Methods:The subjects of the study were 50 patients with advanced breast cancer who were admitted to our hospital between March 2016 and March 2019.They were divided into groups A and B with 25 cases each.The subjects of these two groups were treated conventional method,respectively.And then,Capecitabine maintenance therapy was continued for group A,clinical observation for groups B.Progressionfree survival(PFS)was compared between the two groups.Results:The median PFS was 14.2 months for group A and 8.9 months for group B(P<0.05).The complication rate of group A was 24.0%compared to that of group B was 22.0%(P>0.05).Conclusion:The patients with advanced breast cancer who received Cap maintenance therapy were benefited from better curative effect and controllable complications,which has high promotion value.
